Key TakeawaysMenopause hormone therapy appears to boost the effectiveness of tirzepatide (Zepbound)Women lost more weight with the combo, and more women lost at least 20% of body weightThe findings reflect earlier results with semaglutide (Wegovy).MONDAY, July 14, 2025 (HealthDay News) Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new study says.Women using tirzepatide (Zepbound) lost more weight if they also were taking hormone therapy 17% of body weight lost versus 14% after a median 18 months, researchers reported Saturday at the Endocrine Societys annual meeting in San Francisco.Further, more women taking Zepbound and hormone therapy achieved at least 20% total body weight loss, with 45% meeting this goal compared to 18% of those not on hormone therapy.These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women, presenting investigator Dr
BioAge is among several pharma companies looking to develop oral muscle preserving drugs with obesity-focused partners
Chen, X., & Jones, I
This has been investigated and proven in studies by Brass (Brass and Ruff, 1989, Brass and Stabler, 1988)
These preliminary findings urge future in-depth studies on how to modulate Klotho expression through dietary interventions to improve DKD
Tirzepatide works best when combined with lifestyle changes, including a reduced-calorie diet and increased physical activity
